Ryzneuta® (Efbemalenograstim alfa-vuxw), sold under the brand name 亿立舒® in china, is a leukocyte growth factor used for reducing the incidence of infection, as manifested by febrile neutropenia (FN), in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer medicines associated with a clinically significant incidence of febrile neutropenia (FN).
Chinese Version
Brand name：Ryzneuta (亿立舒)
INN name：Efbemalenograstim alfa (艾贝格司亭α注射液)
Manufacturer：Evive Biotech (亿一生物)
Packaging：20mg/1ml/Box
Inquire&E-mail: care@100pei.com
It was approved for medical use in China in May 2023, and the United States in November 2023. November 16, 2023 – The FDA approved Evive Biotechnology’s Ryzneuta (efbemalenograstim alfa-vuxw), to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
扫一扫 
